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estimated $24,940,983,900.00 ($24.9B) in wages are lost from 43,750 years of foregone 
employment, yielding a total ten year cGvHD cost burden of $30,214,063,841.50 
($30.2B). ConClusions: The human capital perspective should be considered in 
making policy recommendations for coverage of cGvHD treatments that affect those, 
including Central and South American patients, who survice acute complications 
of allogeneic transplantation.
PSY6
CoSt-EffECtivEnESS of RomiPloStim AS fiRSt-linE PRimARY immunE 
thRomboCYtoPEniA (itP) tREAtmEnt in Adult SPlEnECtomiSEd PAtiEntS 
Who ARE REfRACtoRY to othER tREAtmEntS And AS SECond-linE itP 
tREAtmEnt in Adult non-SPlEnECtomiSEd PAtiEntS WhERE SuRgERY iS 
ContRAindiCAtEd in ColombiA
Vargas-Valencia J1, Garcia Perlaza J2
1Econopharma Consulting, Mexico, Mexico, 2AMGEN, Bogotá, Colombia
objeCtives: To conduct a cost-effectiveness analysis of romiplostim as first-line 
ITP treatment in adult splenectomised patients who are refractory to other treat-
ments and as second-line treatment in adult non-splenectomised patients for 
whom surgery is contra-indicated vs. eltrombopag. Methods: A Markov model 
with embedded decision tree containing three health status (platelets≥ 50× 109/L; 
platelets< 50× 109/L; and dead) was developed from a Colombian Health Ministry 
perspective and evaluated at 4-week cycles over a lifetime horizon. Efficacy was 
characterized by initial response; mean time to response, and duration of response 
and was estimated from literature review. Used resources and treatment patterns 
were obtained by a modified Delphi panel from a group of four hematologist. Costs 
include drug administration, visits, laboratory tests, rescue therapy, intracranial, GI 
and gynecological bleeding. Social Security costs (ISS+30) are used for procedures, 
visits and laboratory tests; and SISMED-2014 prices for drugs. Clinical benefits and 
costs are discounted 5% per annum. Results: Total expected treatment cost for 
romiplostim arm was $1,276,302,002 (romiplostim cost $408,991,91; subsequent 
treatment lines $4,612,365; rescue therapy (IVIg and IV steroids) $859,929,341; and 
bleedings $2,768,379) vs. $1,315,173,138 for eltrombopag arm (eltrombopag cost 
$191,795,316; subsequent treatment lines $5,836,389; rescue therapy $1,113,981,314; 
and bleedings $3,560,119). Use of romiplostim, compared with eltrombopag, 
increased 4.46 years response duration, prevented 4.5 bleeding episodes and 
1.5 admissions over a lifetime horizon. Romiplostim proves to be the dominant 
approach compared with eltrombopag. ConClusions: Use of romiplostim in the 
ITP treatment pathway, compared with eltrombopag, improves clinical outcomes, 
by increasing and maintaining platelet count, reducing bleeding events and rescue 
therapy need. These benefits generate cost savings and positioning romiplostim 
as a dominant approach.
PSY7
SYStEmAtiC REviEW And CoSt-EffECtivEnESS AnAlYSiS of dRug uSEd in 
obESitY tREAtmEnt in bRAzil, undER hEAlth SYStEm PERSPECtivE
Vianna CM1, Fernandes RR1, Mosegui GB2, Gomes F1
1UERJ, Rio de Janeiro, Rio de Janeiro, Brazil, 2Universidade Federal Fluminense, Niterói, Brazil
objeCtives: Present a systematic review of efficacy, effectiveness and safety 
of pharmacological treatments (sibutramine and orlistat) used in obesity treat-
ment and performs a cost-effectiveness analysis comparing: (a) Diet; (b) diet plus 
sibutramine and (c) diet plus orlistat under the public health system perspec-
tive. Methods: A systematic review of literature produced the estimates of co-
morbidities risks and disease progression with and without the interventions. 
A Markov model that simulates related obesity comorbidities as chronicle heart 
disease and diabetes mellitus was build. Discount rate assumed was 5% and the 
outcome data was taken from international literature and was measured by QALY. 
Direct cost was calculated by the authors using data from public health system 
databases, as well as in related cost studies made in Brazil. PARTIAL Results: 
The systematic review has initially provided results of effectiveness of the inter-
ventions. Weight loss values after one year of treatment ranged from -6,35 kg to 
sibutramine 15mg and -2,89kg to standard care (only Diet). All patient gain weight 
after intervention in a rate of 0,385kg/month (first four years), and at 1kg/year in 
the next years. Annual costs of co-morbidities were estimated in U$7,017.00 to 
infarction and U$1,335.00 to diabetes. ConClusions: More data will be collected, 
to complement this preliminary serving as input to complete de cost-effectiveness 
model.
PSY8
CoSt-minimiSAtion AnAlYSiS of dExmEdEtomidinE vERSuS PRoPofol in 
mEChAniCAl vEntilAtEd PAtiEntS At iCu
Athanazio R1, Maldini P2, Roa S3, Turunen H4, Silva C5
1Eurotrials, Scientific Consultants, São Paulo, Brazil, 2Eurotrials, Scientific Consultants, Santiago, 
Chile, 3Eurotrials, Scientific Consultants, Buenos Aires, Argentina, 4Orion Corporation Orion 
Pharma, Espoo, Finland, 5Eurotrials, Scientific Consultants, Lisbon, Portugal
objeCtives: To evaluate costs associated with the use of dexmedetomidine 
in comparison with conventional clinical practice in Portugal in intensive care 
unit (ICU) patients through a cost-minimisation and a budget impact analy-
sis. Methods: The population consisted of ICU ventilated patients requiring a 
mild to moderate level of sedation. Time spent at ICU was estimated based on a 
head-to-head published clinical trial (PRODEX) comparing the two sedatives. The 
time horizon was inpatient stay at ICU considering three periods: mechanical 
ventilation, non-mechanical ventilation and off ventilator. The analysis considered 
the Portuguese National Health Service perspective and only included ICU stay and 
sedative costs, which were extracted from Portuguese official sources (2014 prices). 
Sensitivity analyses were performed. Results: The estimated mean costs per ICU 
patient discharge were € 13,950 for dexmedetomidine and € 14,711 for propofol 
resulting in a cost-saving of € 761 per patient. Sensitivity analysis confirmed sav-
ings upon the use of dexmedetomidine ranging from € 598 to € 1,418. Introducing 
dexmedetomidine in hospitals for sedation in ICU would result in yearly savings of 
SYStEmiC diSoRdERS/ConditionS – Cost Studies
PSY3
mAttERS of WEight: finAnCiAl buRdEn of ovERWEight And obESitY in 
mExiCo
Sansores DN1, Gutiérrez-Delgado C2
1Secretaría de Salud, México, D.F., Mexico, 2Economic Analysis Unit, Mexico City, Mexico
objeCtives: Estimate direct and indirect costs generated by eight diseases related 
to O&O in Mexican population for the period 1999-2023. Methods: Data on diabe-
tes, cardiovascular disorders (CVD), osteoartritis, and malignant tumors (esopha-
gus, pancreas, breast, cervix, colo-rectal) are analyzed for 2004-2013. Cost of illness 
approach was used for direct cost estimates; Indirect costs are estimated by the 
human capital approach that includes lost income for premature death (LIPD), tem-
porary disability subsidies (TDS), permanent disability pension (PDP) and opportu-
nity cost for the non-medical care giver (OCC). Results: Annual average direct costs 
generated by selected diseases related to O&O represented 17% of the total public 
medical care expenditure (0.1% of GDP) of 2013. Diabetes and CVD contributed with 
80% of such costs. Annual average indirect costs represented 0.2% of GDP of 2013 and 
are dominated by LIPD (64%) followed by PDP (19%) and OCC (10%). ConClusions: 
Findings show the need of continue efforts to address the challenge posed by O&O 
for both the Mexican health care system in terms of financial sustainability and 
the Mexican society as a whole in terms of significant reductions in productivity 
in the short and midterms. Of particular relevance is the recent implementation 
of the National Strategy to Prevent and Control O&O and Diabetes which should 
be monitored and evaluated in order to document effectiveness of public policy 
interventions in the O&O arena for the Mexican case.
PSY4
ACRomEgAlY PAtiEntS With inAdEquAtE RESPonSE to mAximum doSE 
oCtREotidE-lAR Who PRogRESS to tREAtmEnt With PEgviSomAnt: 
EConomiC EvAluAtion And inCREmEntAl budgEt imPACt AnAlYSiS fRom 
thE PubliC PERSPECtivE to São PAulo StAtE
Ferreira CN1, Rufino C1, Santana CF2
1Pfizer Brasil, São Paulo, Brazil, 2Pfizer, São Paulo, Brazil
objeCtives: This study evaluated the cost-effectiveness of pegvisomant com-
pared to octreotide-LAR and the incremental Budget Impact Analysis (iBIA) from 
the public perspective in São Paulo State Health Secretariat (SHS/SP). Methods: 
The economic evaluation assumed octreotide-LAR to be first line treatment as 
(recommended to acromegaly Ministry of Health Brazilian guideline). In certain 
clinical conditions patients who fail to achieve biochemical control will receive 
octreotide-LAR staggered dose (off-label use). This population was used for the 
analysis, and compared to a population of patients with acromegaly treated with 
pegvisomant. To estimate costs and treatment outcomes, a Markov model was 
developed, representing the control rate of patients treated with pegvisomant or 
maintained dose staggered octreotide-LAR. All patients entering the model who 
were unresponsive to the maximum octreotide-LAR dose based on the transition 
risk and according to control or non-control of disease, patients could transition 
to one of the following states: control; non-control and death (absorbing state). 
A time horizon of 35 years was assumed and a discount rate of 5% per annum 
was applied. The outcomes of interest were: “years of life” and “years living with 
disease control”. To estimated number of SHS/SP eligible patients, the epidemio-
logical demand method was applied that resulted in 210 patients (2015). Results: 
The iBIA was estimated to increase by 24.87% of current spending, if pegvisomant 
is reimbursed by the government in SHS/SP. for “year of life” and “years living 
with disease control” were 0.46 and 1.37 years, respectively, and for pegvisomant 
saving BRL 313,599.84. The final result did not change; the sensitivity analysis 
demonstrated the model robustness. ConClusions: Pegvisomant is a dominant 
technology compared to octreotide-LAR under the SHS/SP and it may represent a 
feasible treatment option for patients with acromegaly in the acromegaly treat-
ment in SHS/SP.
PSY5
buRdEn of CoSt in ChRoniC gRAft vERSuS hoSt diSEASE folloWing 
hEmAtoPoiEtiC StEm CEll tRAnSPlAntAtion: PREdiCtionS foR thE nExt 
dECAdE
Jonesn’ CA1, Fernandez L1, Mesa OA2, Weimersheimer P1, Peters C3
1University of Vermont College of Medicine, Burlington, VT, USA, 2Therakos, Inc., Wokingham, 
Berkshire, UK, 3Therakos, Inc., West Chester, PA, USA
objeCtives: With advances to treating acute graft-versus-host-disease (aGvHD), 
chronic graft-versus-host disease (cGvHD) has become a focus of morbidity fol-
lowing allogeneic hematopoietic stem cell transplantion. Given that cGvHD often 
presents years following a transplant, our objective was to estimate its burden 
of cost based on published estimates of incidence, morbidity, lost work time and 
survivorship. Methods: Treatment pathways and adverse events were evaluated 
in terms of direct cost from published sources. Additional cost estimates for read-
mission and follow-up care were annualized and compared between non-cGvHD 
patients and grades I-IV of cGvHD over a 5 year horizon, based on studies conducted 
in the United States and United Kingdom. Indirect costs (or benefits) were calculated 
based on age-adjusted United States Census Bureau reported average wages, wage 
growth and the probability that with illness these would be foregone. Results: 
The total burden of cost from cGvHD is far more poignant when viewing long-term 
and morbidity, mortality and consequent wages foregone, even as compared with 
the cost of transplant and normative follow-up. Relapse due to primary disease 
(29%) and cGvHD (22%) were reported by the literature to be the leading causes 
of premature mortality. This is important in the counter-factual scenario where 
patients might have returned to normal daily activities. With the burden of cost for 
cGvHD presented as a summation of direct and indirect components, aggressive 
upfront treatments may have a potential to reduce long-term complications and 
maintain the ability to return to daily functioning. From the societal perspective, an 
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 8 0 5 – A 8 8 1  A843
body mass index (BMI) ≥ 30. 62.2% of respondents reported taking steps to lose weight. 
These respondents were more likely to be female, of higher socioeconomic status, 
and more knowledgeable about their health (all p< .05). Among respondents who 
were trying to lose weight, only 27.5% had consulted a specialist. The primary reason 
for weight loss was to improve health (60.8%). Despite these intentions, success was 
limited. Only 34.3% reported having lost weight in the past 6 months (43.3% reported 
gaining weight) and the mean weight change was 0.5 kilograms (SD = 7.3). The most 
common treatments used for weight loss included exercise and dieting; 27.6% and 
17.1% of respondents have used an over the counter (OTC)/herbal product and a 
prescription medication, respectively. Discontinuation rates were high with these 
treatments, as only between 28.0% and 48.8% of respondents who ever used OTC/
herbal products and prescription medications, were currently using those methods. 
Mean monthly out-of-pocket costs for OTC and prescription medications (combined) 
did not vary by socioeconomic status. ConClusions: The majority of respondents 
were taking steps to lose weight, employing a variety of strategies. Unfortunately, suc-
cess of these strategies was limited. Additional weight loss treatments and increased 
obesity management advice may help improve weight loss success.
PSY13
thE buRdEn of obESitY in mExiCo: PREvAlEnCE, ComoRbiditiES, And 
ASSoCiAtionS With quAlitY of lifE, RESouRCE utilizAtion And 
PRoduCtivitY
DiBonaventura MD1, Le Lay A2, Fournier J2, Kull K2, Olmos HC3, Mille I3, Bjørke B2, Bakker 
E3, Ehrenreich A1
1Kantar Health, New York, NY, USA, 2Novo Nordisk A/S, Bagsværd, Denmark, 3Novo Nordisk A/S, 
Mexico City, Mexico
objeCtives: This study investigated the effect of body mass index (BMI) and related 
comorbidities on quality of life, work productivity, activity impairment, healthcare 
resource utilization, and associated costs in Mexico. Methods: Data were collected 
using a cross-sectional survey of adults in Mexico (N= 2,511) identified from a combi-
nation of Internet panels and offline recruitment. Recruitment was made to ensure 
the demographic composition of the sample mimicked the total adult population. 
The analysis focused on respondents with normal weight (BMI≥ 18.5 & < 25 kg/m2), 
overweight (BMI≥ 25 & < 30 kg/m2), obesity class I (BMI≥ 30 & < 35 kg/m2), class II 
(BMI≥ 35 & < 40 kg/m2), or class III (BMI≥ 40 kg/m2). Demographics, comorbidities (e.g., 
hypertension, dysglycaemia), health outcomes such as quality of life (EQ-5D), work 
productivity and activity impairment (WPAI questionnaire), healthcare resource utili-
zation, and indirect costs were assessed. Generalized linear models were used to test 
the association between BMI levels and health outcomes, controlling for covariates 
(e.g., age, sex, comorbidities). Results: The sample was 50.6% male with a mean age 
of 40.7 years (SD= 14.5); 38.3% were overweight and 24.4% reported a BMI≥ 30. 75.2% of 
individuals with BMI ≥ 35 had dysglycaemia (29.9% type 2 diabetes mellitus (T2DM) 
and 45.3% pre-diabetes). Increasing BMI was associated with significant impairment 
in quality of life (health utilities ranging from 0.84 for normal weight, down to 0.76 for 
people with BMI≥ 35). Increasing BMI was also associated with greater overall work 
impairment (from 18.8% up to 25.8%), activity impairment (from 15.8% up to 24.8%), 
and indirect costs (from 35122 MXN up to 48090 MXNs). A similar pattern of results 
was found in the T2DM, pre-diabetes, and hypertension subgroups. ConClusions: 
Results suggest a significant effect of increasing BMI and comorbidities on quality of 
life and work productivity. Improvement in the management of the obesity epidemic 
could have significant benefits to the patient and society.
PSY14
lEPtoSPiRoSiS; A zoonotiC, moRbid And fAtAl diSEASE: A RECoRd 
viEWing StudY
Mallhi TH1, Khan AH1, Adnan AS2, Sarriff A1, Jummaat F3, Khan YH1
1Universiti Sains Malaysia, Pulau Pinang, Malaysia, 2Hospital Universiti Sains Malaysia, 
Kelantan, Malaysia, 3School of Medical Sciences, Kelantan, Malaysia
objeCtives: Leptospirosis is a zoonotic infection endemic in Malaysia. This study 
was conducted to describe the clinical features and laboratory findings of leptospi-
rosis in a tertiary care hospital of Malaysia Methods: This is a retrospective study 
including 79 consecutive patients with leptospirosis admitted to tertiary hospitals in 
Kelantan, Malaysia from 2009 to 2011. All patients had clinical and epidemiological 
data suggestive of leptospirosis, and positive laboratorial test for leptospirosis were 
included in this study. Hospital database were used to extract all the required infor-
mation Results: A total of 79 patients (mean age: 36.8 ± 12.4 years) were included 
among them 68.5% were male. Duration of symptoms onset to hospital admission 
was 6.7 ± 2.6 days. The most common clinical findings among patients at admis-
sion were arthralgia (90.1%), fever (86.5%), jaundice (98.3%) and myalgia (87.2%). 
Other common clinical manifestations were abdominal discomfort (78.8%), leth-
argy (33.2%) headache (68.2%), vomiting (82.4%), bleeding (39.9%) and dehydration 
(72.6%). Among leptospiral intricacies hepatic failure (66.4%), acute kidney injury 
(69.5%), acute respiratory distress syndrome (2.2%), pulmonary failure (33.1%), visual 
impairments (3.6%), rhabdomyolosis (12.2%) of the patients. Thrombocytopenia and 
hematuria were observed in 58.3% and 34.2% of total cases respectively. Mean days 
of hospitalization were 6.2 ± 2.3 days. Mortality was observed in 11 cases (14%). All 
the fatal cases have more than one organ failure ConClusions: Leptospirosis is 
zoonotic fatal and highly morbid disease. Several clinical complications associ-
ated with leptospirosis lead to high mortality and morbidity. Early diagnosis and 
adequate management can reduce morbidity and mortality associated with lep-
tospirosis
SYStEmiC diSoRdERS/ConditionS – health Care use & Policy Studies
PSY15
nuEvAS moléCulAS REgiStRAdAS En ChilE duRAntE El Año 2014
Balmaceda C1, Espinoza MA2
1Instituto de Salud Publica de Chile, Santiago, Chile, 2Catholic University of Chile, Santiago, Chile
at least € 457K for the Portuguese NHS. ConClusions: Dexmedetomidine reduces 
the duration of mechanical ventilation and is a cost-saving alternative to propofol 
at the ICU setting.
PSY9
CoSt-minimizAtion AnAlYSiS of thE CARboxYmAltoSE fERRiC (i.v.) 
ComPAREd With SACARAto fERRiC (i.v.) in thE tREAtmEnt of AnEmiA 
undER SuPlEmEntARY hEAlth CARE PERSPECtivE
Vicente AB, Decimoni TC, Quero AA
Takeda Brasil, São Paulo, Brazil
objeCtives: Absolute iron deficiency related to depletion of iron stores or func-
tional iron deficiency are the main causes of anemia, which can trigger hospitali-
zation and even mortality. International guidelines recommend intravenous (IV) 
iron therapy for several chronic conditions. Intravenous iron is more effective, 
better tolerated, and improves the quality of life to a greater extent than oral 
iron supplements. Ferric carboxymaltose (FCM) and iron sucrose (IS) are IV iron 
drugs available in the Brazilian market. Considering this scenario the purpose 
of the study is to perform a cost minimization analysis of FCM versus IS under 
the supplementary health setting. Methods: Due to no non-inferiority study 
design comparing both IV therapies, a cost-minimization analysis was conducted. 
Treatment expenditures were accounted considering drugs acquisition costs and 
infusion related costs. Drugs ex-factory prices were obtained in official price list. 
Infusion fees were accessed through research conducted in 36 private hospitals 
distributed in service categories. In each institution the information collected 
was: place of infusion, materials, medical honoraries, room fee and price lists. An 
average patient was assumed (70kg; Hb≤ 10,5g/dL) which would receive a total iron 
dose of 1,000mg in both regimens. According to label, FCM can be administrated in 
a single dose whereas IS requires 5 infusions of 200 mg iron given up twice weekly. 
Deterministic one-way sensitivity analysis was performed. Costs were reported in 
Brazilian currency. Results: Treatment cost for FCM (BRL927.69) was lower than 
IS (BRL 1,184.97), due to more infusions required for treatment with IS. The number 
and cost of the infusions were the most influential parameters in the analysis, 
and even with variations of ± 20% in all parameters, treatment results with FCM 
remained favorable. ConClusions: FCM represents a cost-saving option com-
pared with other IV therapy alternative used in the management of anaemia in 
the Brazilian Supplementary Health System.
PSY10
CoSt-minimizAtion AnAlYSES of AdAlimumAb ComPAREd With 
SElECtivE immunoSuPPRESSivE CYtokinES bloCkERS And inhibitoRS 
of tumoR nECRoSiS fACtoR AlPhA indiCAtEd foR thE tREAtmEnt of 
RhEumAtoid ARthRitiS, PSoRiASiS And CRohn’S diSEASE in thE PRivAtE 
mARkEt in mExiCo
Pichardo-Piña CA, Sánchez-Casillas JL, Pozos-Espíndola JC
AbbVie, Distrito Federal México, Mexico
objeCtives: To compare the cost of treating rheumatoid arthritis, psoriasis and 
Crohn’s disease with adalimumab compared with selective immunosuppressive 
cytokines blockers and inhibitors of tumor necrosis factor-alpha. Methods: We 
conducted a through systemic review of the literature and compared data from 
adalimumab with etanercept, abatacept, infliximab, tocilizumab, certolizumab 
pegol and golimumab in treating rheumatoid arthritis, with etanercept, inflixi-
mab, and ustekinumab in the treatment of plaque psoriasis, and with infliximab 
and certolizumab pegol in the treatment of Crohn’s disease. A cost minimization 
analysis was then considered appropriate under the perspective of a private health 
care provider in Mexico and a time horizon of five years. The costs of medication 
and application (2014) were considered. It has been assumed that patients have 
a weight of 70 kg based on the National Health and Nutrition Survey 2012 and a 
discount rate of 5% was applied. Results: Adalimumab proved to be less expen-
sive in the base case against considered alternatives. The total discounted cost of 
using adalimumab for 5 years for rheumatoid arthritis was $ 1,030,807.61 (followed 
by abatacept -$1,032,233.83- and certolizumab -$1,093,401.30-); in the case of pso-
riasis was $ 1,047,883.48 (followed by ustekinumab -$1,210,738.82- and etanercept 
-$1,237,387.15-); for Crohn’s disease was $ 1,072,947.28 (followed by infliximab 
-$1,353,574.18- and certolizumab -$2,091,555.72-). ConClusions: Treatment with 
adalimumab incurs lower costs compared with etanercept, abatacept, infliximab, 
tocilizumab, certolizumab pegol and golimumab in treating rheumatoid arthritis; 
etanercept, infliximab, and ustekinumab in the treatment of psoriasis and certoli-
zumab pegol and infliximab in treating Crohn’s disease. Further budget impact 
and probabilistic sensitivity analyses could provide additional information about 
these alternatives.
SYStEmiC diSoRdERS/ConditionS – Patient-Reported outcomes & Patient 
Preference Studies
PSY12
WEight loSS tREAtmEnt PAttERnS in mExiCo
DiBonaventura MD1, Le Lay A2, Fournier J2, Kull K2, Olmos HC3, Mille I3, Bjørke B2, Bakker 
E3, Ehrenreich A1
1Kantar Health, New York, NY, USA, 2Novo Nordisk A/S, Bagsværd, Denmark, 3Novo Nordisk A/S, 
Mexico City, Mexico
objeCtives: This study investigated the treatment patterns of those who are attempt-
ing to lose weight in Mexico. Methods: Data were collected using a cross-sectional 
survey of adults in Mexico (N= 2,511) identified from a combination of internet panels 
and offline recruitment. Recruitment was made to ensure the demographic composi-
tion of the sample mimicked that of the total adult population. Respondents provided 
data on their demographics, health history, weight loss intentions and treatments 
used, weight change, and out-of-pocket costs. Results: The sample was 50.6% male 
with a mean age of 40.7 years (SD= 14.5); 38.3% were overweight and 24.4% reported a 
